Latest news
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law - TradingViewTradingView · Mon, 03 Aug 2026 06:22:00 GMTMapLight Therapeutics stock crashes on Phase II schizophrenia data - Clinical Trials ArenaClinical Trials Arena · Tue, 28 Jul 2026 14:17:49 GMTMapLight's schizophrenia candidate clears one bar but misses another - The Pharma LetterThe Pharma Letter · Tue, 28 Jul 2026 07:00:00 GMTMapLight’s schizophrenia pill remains in Cobenfy’s shadow after mixed Phase 2 readout - BioSpaceBioSpace · Mon, 27 Jul 2026 07:00:00 GMTMapLight dives despite positive data for schizophrenia drug - BioPharma DiveBioPharma Dive · Mon, 27 Jul 2026 07:00:00 GMT